{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:52:15Z","timestamp":1784019135482,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s41669-024-00554-y","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:59:48Z","timestamp":1743728388000},"page":"365-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Economic Burden of Acute Myeloid Leukemia in European Union: Results from a Systematic Review of Literature"],"prefix":"10.1007","volume":"9","author":[{"given":"Alisha","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zermina","family":"Tasleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail Ayaz","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anees","family":"ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qurratul Ain","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajra","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayah","family":"Karuniawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3420-4752","authenticated-orcid":false,"given":"Saleh Karamah","family":"Al-Tamimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"554_CR1","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010.","journal-title":"Nat Rev Dis Primers"},{"key":"554_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/JBM.S279736","volume":"12","author":"A Forsythe","year":"2021","unstructured":"Forsythe A, Sandman K. What does the economic burden of acute myeloid leukemia treatment look like for the next decade? An analysis of key findings, challenges, and recommendations. J Blood Med. 2021;12:245\u201355.","journal-title":"J Blood Med"},{"key":"554_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-020-00170-6","volume":"9","author":"Y Dong","year":"2020","unstructured":"Dong Y, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14.","journal-title":"Exp Hematol Oncol"},{"key":"554_CR4","unstructured":"Global Cancer Observatory. Available from: https:\/\/gco.iarc.fr\/."},{"issue":"1","key":"554_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medicina54010005","volume":"54","author":"N Maksimovic","year":"2018","unstructured":"Maksimovic N, et al. Incidence and mortality patterns of acute Myeloid Leukemia in Belgrade, Serbia (1999\u20132013). Medicina (Kaunas). 2018;54(1):5.","journal-title":"Medicina (Kaunas)"},{"issue":"16 Suppl","key":"554_CR6","first-page":"S347","volume":"24","author":"M Wiese","year":"2018","unstructured":"Wiese M, Daver N. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care. 2018;24(16 Suppl):S347-s355.","journal-title":"Am J Manag Care"},{"key":"554_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2018.06.010","volume":"71","author":"JA Bell","year":"2018","unstructured":"Bell JA, et al. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018;71:27\u201333.","journal-title":"Leuk Res"},{"issue":"21","key":"554_CR8","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1182\/blood.V120.21.3614.3614","volume":"120","author":"D Mahmoud","year":"2012","unstructured":"Mahmoud D, et al. Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease. Blood. 2012;120(21):3614.","journal-title":"Blood"},{"key":"554_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2016.03.009","volume":"46","author":"AL Van de Velde","year":"2016","unstructured":"Van de Velde AL, et al. Medical costs of treatment and survival of patients with acute myeloid leukemia in Belgium. Leuk Res. 2016;46:26\u20139.","journal-title":"Leuk Res"},{"issue":"8","key":"554_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/17474086.2019.1627869","volume":"12","author":"JP Bewersdorf","year":"2019","unstructured":"Bewersdorf JP, et al. Healthcare expenses for treatment of acute myeloid leukemia. Expert Rev Hematol. 2019;12(8):641\u201350.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"554_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/jha2.208","volume":"2","author":"E Hernlund","year":"2021","unstructured":"Hernlund E, et al. Socioeconomic cost of AML in Sweden-A population-based study using multiple nation-wide registers. EJHaem. 2021;2(3):385\u201393.","journal-title":"EJHaem"},{"issue":"10","key":"554_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","volume":"62","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.","journal-title":"J Clin Epidemiol"},{"key":"554_CR13","unstructured":"International prospective register of systematic reviews (PROSPERO). Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42024537725."},{"issue":"2","key":"554_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002742","volume":"16","author":"OM Dekkers","year":"2019","unstructured":"Dekkers OM, et al. COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology. PLoS Med. 2019;16(2): e1002742.","journal-title":"PLoS Med"},{"issue":"Pt 1","key":"554_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.envint.2018.07.015","volume":"121","author":"RL Morgan","year":"2018","unstructured":"Morgan RL, et al. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int. 2018;121(Pt 1):1027\u201331.","journal-title":"Environ Int"},{"issue":"8","key":"554_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","volume":"29","author":"A Larg","year":"2011","unstructured":"Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653\u201371.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"554_CR17","first-page":"464","volume":"1","author":"KG Sam","year":"2009","unstructured":"Sam KG, Philip M. Pharmacoeconomics: cost of illness studies. Hygeia. 2009;1(1):464\u20139.","journal-title":"Hygeia"},{"issue":"1","key":"554_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10198-008-0101-x","volume":"10","author":"SS Tan","year":"2009","unstructured":"Tan SS, et al. Comparing methodologies for the cost estimation of hospital services. Eur J Health Econ. 2009;10(1):39\u201345.","journal-title":"Eur J Health Econ"},{"key":"554_CR19","unstructured":"Euro foreign exchange reference rates. Available from: https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/euro_reference_exchange_rates\/html\/eurofxref-graph-usd.en.html."},{"key":"554_CR20","unstructured":"Webster, I. Euro inflation calculator. Available from: https:\/\/www.in2013dollars.com\/Euro-inflation."},{"issue":"1","key":"554_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/2191-1991-3-28","volume":"3","author":"C Crespo","year":"2013","unstructured":"Crespo C, et al. Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain. Health Econ Rev. 2013;3(1):28.","journal-title":"Health Econ Rev"},{"key":"554_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2147\/CEOR.S222879","volume":"11","author":"A Arenaza","year":"2019","unstructured":"Arenaza A, et al. Cost-effectiveness of midostaurin in the treatment of acute myeloid leukemia with the FLT3 mutation in Spain. Clinicoecon Outcomes Res. 2019;11:683\u201394.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"4","key":"554_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10198-019-01149-9","volume":"21","author":"G Tremblay","year":"2020","unstructured":"Tremblay G, et al. Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. Eur J Health Econ. 2020;21(4):543\u201355.","journal-title":"Eur J Health Econ"},{"issue":"5\u20136","key":"554_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.tracli.2015.06.249","volume":"22","author":"G Cannas","year":"2015","unstructured":"Cannas G, et al. Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly. Transfus Clin Biol. 2015;22(5\u20136):341\u20137.","journal-title":"Transfus Clin Biol"},{"issue":"2","key":"554_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11096-010-9462-1","volume":"33","author":"V Nerich","year":"2011","unstructured":"Nerich V, et al. Induction-related cost of patients with acute myeloid leukaemia in France. Int J Clin Pharm. 2011;33(2):191\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"554_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cncr.27686","volume":"119","author":"M Michallet","year":"2013","unstructured":"Michallet M, et al. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer. 2013;119(1):107\u201314.","journal-title":"Cancer"},{"issue":"12","key":"554_CR27","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1097\/01.TP.0000129409.84087.62","volume":"77","author":"H Esp\u00e9rou","year":"2004","unstructured":"Esp\u00e9rou H, et al. Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicentre, French study. Transplantation. 2004;77(12):1854\u20138.","journal-title":"Transplantation"},{"issue":"9","key":"554_CR28","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41409-018-0133-5","volume":"53","author":"M Debals-Gonthier","year":"2018","unstructured":"Debals-Gonthier M, et al. Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years. Bone Marrow Transplant. 2018;53(9):1096\u2013104.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"554_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3324\/haematol.2013.092254","volume":"99","author":"M Labopin","year":"2014","unstructured":"Labopin M, et al. Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France. Haematologica. 2014;99(3):535\u201340.","journal-title":"Haematologica"},{"issue":"7","key":"554_CR30","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bmt.1705109","volume":"36","author":"C Cordonnier","year":"2005","unstructured":"Cordonnier C, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005;36(7):649\u201354.","journal-title":"Bone Marrow Transplant"},{"key":"554_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00282-000-0149-2","volume":"42","author":"F Schwarzenbach","year":"2000","unstructured":"Schwarzenbach F, et al. Cost analysis of allogeneic bone marrow transplantation. Hematol Cell Ther. 2000;42:149\u201354.","journal-title":"Hematol Cell Ther"},{"issue":"8","key":"554_CR32","first-page":"813","volume":"93","author":"P Fagnoni","year":"2006","unstructured":"Fagnoni P, et al. Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification. Bull Cancer. 2006;93(8):813\u20139.","journal-title":"Bull Cancer"},{"issue":"3","key":"554_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.leukres.2012.09.018","volume":"37","author":"A Leunis","year":"2013","unstructured":"Leunis A, et al. The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res. 2013;37(3):245\u201350.","journal-title":"Leuk Res"},{"issue":"1","key":"554_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/152581601750098499","volume":"10","author":"CA Uyl-de Groot","year":"2001","unstructured":"Uyl-de Groot CA, et al. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlands. J Hematother Stem Cell Res. 2001;10(1):187\u201392.","journal-title":"J Hematother Stem Cell Res"},{"issue":"4","key":"554_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/sj.bmt.1703641","volume":"30","author":"M van Agthoven","year":"2002","unstructured":"van Agthoven M, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. 2002;30(4):243\u201351.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"554_CR36","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00277-012-1530-2","volume":"91","author":"HM Blommestein","year":"2012","unstructured":"Blommestein HM, et al. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol. 2012;91(12):1945\u201352.","journal-title":"Ann Hematol"},{"issue":"4","key":"554_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/ejh.13740","volume":"108","author":"G van Gorkom","year":"2022","unstructured":"van Gorkom G, et al. The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands. Eur J Haematol. 2022;108(4):327\u201335.","journal-title":"Eur J Haematol"},{"issue":"10","key":"554_CR38","first-page":"480","volume":"148","author":"MT Groot","year":"2004","unstructured":"Groot MT, et al. The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation. Ned Tijdschr Geneeskd. 2004;148(10):480\u20134.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"8","key":"554_CR39","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.3390\/cancers14081921","volume":"14","author":"A Solana-Altabella","year":"2022","unstructured":"Solana-Altabella A, et al. Healthcare resource utilization among patients between 60\u201375 years with secondary acute myeloid leukemia receiving intensive chemotherapy induction: a Spanish retrospective observational study. Cancers (Basel). 2022;14(8):1921.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"554_CR40","first-page":"1087","volume":"86","author":"MG Vicent","year":"2001","unstructured":"Vicent MG, et al. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies. Haematologica. 2001;86(10):1087\u201394.","journal-title":"Haematologica"},{"issue":"30","key":"554_CR41","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1200\/JCO.2006.06.4238","volume":"24","author":"F Fern\u00e1ndez-Avil\u00e9s","year":"2006","unstructured":"Fern\u00e1ndez-Avil\u00e9s F, et al. Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol. 2006;24(30):4855\u201361.","journal-title":"J Clin Oncol"},{"issue":"5","key":"554_CR42","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41409-019-0768-x","volume":"55","author":"G Guti\u00e9rrez-Garc\u00eda","year":"2020","unstructured":"Guti\u00e9rrez-Garc\u00eda G, et al. A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. Bone Marrow Transplant. 2020;55(5):965\u201373.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"554_CR43","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1080\/13696998.2020.1840180","volume":"23","author":"A Mars\u00e0","year":"2020","unstructured":"Mars\u00e0 A, et al. Epidemiology, management, and economic impact of acute myeloid leukemia and myelodysplastic syndrome in Spain at the hospital level: a claims database analysis. J Med Econ. 2020;23(12):1477\u201384.","journal-title":"J Med Econ"},{"issue":"11","key":"554_CR44","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0025-7753(04)74534-0","volume":"123","author":"JJ S\u00e1nchez-Blanco","year":"2004","unstructured":"S\u00e1nchez-Blanco JJ, et al. Economic cost of peripheral blood progenitor cell transplantation in Spain. Med Clin (Barc). 2004;123(11):401\u20135.","journal-title":"Med Clin (Barc)"},{"issue":"2","key":"554_CR45","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/trf.14440","volume":"58","author":"J Zhao","year":"2018","unstructured":"Zhao J, et al. Blood use in hematologic malignancies: a nationwide overview in Sweden between 2000 and 2010. Transfusion. 2018;58(2):390\u2013401.","journal-title":"Transfusion"},{"issue":"5","key":"554_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/bmt.2011.162","volume":"47","author":"BM Svahn","year":"2012","unstructured":"Svahn BM, et al. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transplant. 2012;47(5):706\u201315.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"554_CR47","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/01.tp.0000226171.43943.d3","volume":"82","author":"BM Svahn","year":"2006","unstructured":"Svahn BM, et al. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation. 2006;82(2):147\u201353.","journal-title":"Transplantation"},{"issue":"12","key":"554_CR48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1159\/000322209","volume":"33","author":"L Eisele","year":"2010","unstructured":"Eisele L, et al. Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs. Onkologie. 2010;33(12):658\u201364.","journal-title":"Onkologie"},{"issue":"3","key":"554_CR49","first-page":"292","volume":"24","author":"R Kuse","year":"2001","unstructured":"Kuse R, et al. Which factors render cost-covering lump-sum charging difficult for the treatment of patients with acute leukemias? Onkologie. 2001;24(3):292\u20134.","journal-title":"Onkologie"},{"issue":"2","key":"554_CR50","first-page":"165","volume":"20","author":"M Clavio","year":"2001","unstructured":"Clavio M, et al. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res. 2001;20(2):165\u201373.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"554_CR51","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.bbmt.2012.04.002","volume":"18","author":"S Matthes-Martin","year":"2012","unstructured":"Matthes-Martin S, et al. Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable. Biol Blood Marrow Transplant. 2012;18(10):1533\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"554_CR52","unstructured":"Statistical themes. Available from: https:\/\/ec.europa.eu\/eurostat\/web\/main\/data\/statistical-themes."},{"issue":"1","key":"554_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5195\/jmla.2019.433","volume":"107","author":"P Ossom Williamson","year":"2019","unstructured":"Ossom Williamson P, Minter CIJ. Exploring PubMed as a reliable resource for scholarly communications services. J Med Libr Assoc. 2019;107(1):16\u201329.","journal-title":"J Med Libr Assoc"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00554-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:03:06Z","timestamp":1745859786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00554-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["554"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00554-y","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"22 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data will be available on request from the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable. This systematic review was conducted using manual data extraction and analysis methods without the use of specialized software or custom coding.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The authors declare that there is no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"No funding was received for this publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AS, ZT, SAM, AUR, SS, QAJ, HS, HK, and SKT made substantial contributions to the conception and design of the study and analysis and interpretation of the data. All the authors drafted the manuscript or revised it critically for important intellectual content. All authors reviewed, critiqued, and approved the final version submitted for publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}